Pacira Pharmaceuticals Reaches New 12-Month High at $93.13 (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) shares reached a new 52-week high during mid-day trading on Friday , Analyst Ratings.Net reports. The stock traded as high as $93.13 and last traded at $92.20, with a volume of 441,333 shares. The stock had previously closed at $88.50.
A number of analysts have recently weighed in on PCRX shares. Analysts at Canaccord Genuity initiated coverage on shares of Pacira Pharmaceuticals in a research note on Friday. They set a “buy” rating and a $109.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities initiated coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, June 17th. They set a “market perform” rating on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pacira Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $93.00 price target on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $81.80.
The stock has a 50-day moving average of $80.53 and a 200-day moving average of $69.42. The company’s market cap is $3.278 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s quarterly revenue was up 216.4% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.54 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.